Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 4139439, 9 pages
https://doi.org/10.1155/2017/4139439
Research Article

Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice

1Department of Biomedical Science, Graduate School, Kyungpook National University, Daegu 41944, Republic of Korea
2Department of Immunology, School of Medicine, Catholic University of Daegu, Daegu 42472, Republic of Korea
3Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea
4Leading-Edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu 41944, Republic of Korea

Correspondence should be addressed to In-Kyu Lee; rk.ca.unk@ieel

Received 1 July 2017; Accepted 19 October 2017; Published 28 November 2017

Academic Editor: Yona Keisari

Copyright © 2017 Seung Hee Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. A. dos Santos, M. A. Carvalho Rodrigues, N. M. Martins, and A. C. dos Santos, “Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update,” Archives of Toxicology, vol. 86, no. 8, pp. 1233–1250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms and renoprotective strategies,” Kidney International, vol. 73, no. 9, pp. 994–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. D. Sánchez-González, F. J. López-Hernández, J. M. López-Novoa, and A. I. Morales, “An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity,” Critical Reviews in Toxicology, vol. 41, no. 10, pp. 803–821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. P. Miller, R. K. Tadagavadi, G. Ramesh, and W. B. Reeves, “Mechanisms of cisplatin nephrotoxicity,” Toxins, vol. 2, no. 11, pp. 2490–2518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. P. Fadini and A. Avogaro, “Cardiovascular effects of DPP-4 inhibition: beyond GLP-1,” Vascular Pharmacology, vol. 55, no. 1–3, pp. 10–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Anagnostis, V. G. Athyros, F. Adamidou et al., “Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control,” Diabetes, Obesity, and Metabolism, vol. 13, no. 4, pp. 302–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Blaslov, T. Bulum, K. Zibar, and L. Duvnjak, “Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7356–7365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Makino, Y. Fujita, and M. Haneda, “Dipeptidyl peptidase-4 inhibitors in progressive kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 1, pp. 67–73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S.-H. Kim, J.-H. Yoo, W. J. Lee, and C.-Y. Park, “Gemigliptin: an update of its clinical use in the management of type 2 diabetes mellitus,” Diabetes and Metabolism Journal, vol. 40, no. 5, pp. 339–353, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Jung, J. Kim, S. H. Kim, S. Kim, and M.-H. Cho, “Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy,” European Journal of Pharmacology, vol. 761, pp. 116–124, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Jung, J. Kim, C.-S. Kim, S.-H. Kim, and M.-H. Cho, “Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1852, no. 12, pp. 2618–2629, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. G.-S. Oh, H.-J. Kim, J.-H. Choi et al., “Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice,” Kidney International, vol. 85, no. 3, pp. 547–560, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Ramesh and W. B. Reeves, “TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity,” The Journal of Clinical Investigation, vol. 110, no. 6, pp. 835–842, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. L. M. Shelton, B. K. Park, and I. M. Copple, “Role of Nrf2 in protection against acute kidney injury,” Kidney International, vol. 84, no. 6, pp. 1090–1095, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. T. Chen, T. H. Tsai, C. C. Yang et al., “Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction,” Journal of Translational Medicine, vol. 11, p. 270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. W. Chang, C. H. Chen, Y. C. Chen et al., “Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors,” Acta Pharmacologica Sinica, vol. 36, no. 1, pp. 119–130, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Bolisetty, A. Zarjou, and A. Agarwal, “Heme oxygenase 1 as a therapeutic target in acute kidney injury,” American Journal of Kidney Diseases, vol. 69, no. 4, pp. 531–545, 2017. View at Publisher · View at Google Scholar
  18. G.-S. Oh, H.-J. Kim, A. Shen et al., “New therapeutic concept of NAD redox balance for cisplatin nephrotoxicity,” BioMed Research International, vol. 2016, Article ID 4048390, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. L. L. F. Glorie, A. Verhulst, V. Matheeussen et al., “DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury,” American Journal of Physiology - Renal Physiology, vol. 303, no. 5, pp. F681–F688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Katagiri, Y. Hamasaki, K. Doi et al., “Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection,” Journal of the American Society of Nephrology, vol. 24, no. 12, pp. 2034–2043, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. E. El-Sahar, M. M. Safar, H. F. Zaki, A. S. Attia, and A. A. Ain-Shoka, “Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: implication of the oxidative-inflammatory-apoptotic pathway,” Life Sciences, vol. 126, pp. 81–86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Onoyama, M. Koda, T. Okamoto et al., “Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice,” Molecular Medicine Reports, vol. 12, no. 5, pp. 6895–6902, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. D. S. El-Agamy, H. M. Abo-Haded, and M. A. Elkablawy, “Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats,” Experimental Biology and Medicine, vol. 241, no. 14, pp. 1577–1587, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-Y. Moon, J. S. Woo, J.-W. Seo et al., “The dose-dependent organ-specific effects of a dipeptidyl peptidase-4 inhibitor on cardiovascular complications in a model of type 2 diabetes,” PLoS One, vol. 11, no. 3, article e0150745, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Ateyya, “Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin,” International Immunopharmacology, vol. 28, no. 1, pp. 571–577, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Tanaka, S. Kume, M. Chin-Kanasaki et al., “Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury,” Biochemical and Biophysical Research Communications, vol. 470, no. 3, pp. 539–545, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Kim, S. Y. Lee, J. S. Kim et al., “Ameliorating effect of gemigliptin on renal injury in murine adriamycin-induced nephropathy,” BioMed Research International, vol. 2017, Article ID 7275109, 10 pages, 2017. View at Publisher · View at Google Scholar
  28. M. J. Sung, D. H. Kim, Y. J. Jung et al., “Genistein protects the kidney from cisplatin-induced injury,” Kidney International, vol. 74, no. 12, pp. 1538–1547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. K. P. Kang, D. H. Kim, Y. J. Jung et al., “Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3012–3020, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Ramesh, B. Zhang, S. Uematsu, S. Akira, and W. B. Reeves, “Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice,” American Journal of Physiology - Renal Physiology, vol. 293, no. 1, pp. F325–F332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Zhang, G. Ramesh, C. C. Norbury, and W. B. Reeves, “Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells,” Kidney International, vol. 72, no. 1, pp. 37–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. M. Aleksunes, M. J. Goedken, C. E. Rockwell, J. Thomale, J. E. Manautou, and C. D. Klaassen, “Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity,” The Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 2–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C. E. Guerrero-Beltrán, P. Mukhopadhyay, B. Horváth et al., “Sulforaphane, a natural constituent of broccoli, prevents cell death and inflammation in nephropathy,” The Journal of Nutritional Biochemistry, vol. 23, no. 5, pp. 494–500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Shiraishi, L. M. Curtis, L. Truong et al., “Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis,” American Journal of Physiology - Renal Physiology, vol. 278, no. 5, pp. F726–F736, 2000. View at Google Scholar
  35. S. Bolisetty, A. M. Traylor, J. Kim et al., “Heme oxygenase-1 inhibits renal tubular macroautophagy in acute kidney injury,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1702–1712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Bolisetty, A. Traylor, R. Joseph, A. Zarjou, and A. Agarwal, “Proximal tubule-targeted heme oxygenase-1 in cisplatin-induced acute kidney injury,” American Journal of Physiology - Renal Physiology, vol. 310, no. 5, pp. F385–F394, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. G.-T. Gang, Y.-H. Kim, J.-R. Noh et al., “Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity,” Toxicology Letters, vol. 221, no. 3, pp. 165–175, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. S. H. Baek, S. H. Kim, J. W. Kim, Y. J. Kim, K.-W. Lee, and K. Y. Na, “Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial,” Trials, vol. 16, no. 1, p. 239, 2015. View at Publisher · View at Google Scholar · View at Scopus